AbbVie (ABBV) Inventory (2012 - 2026)
AbbVie (ABBV) reported Inventory of $5.0 billion for Q1 2026, up 11.56% year-over-year from $4.5 billion in Q1 2025, and up 1.98% quarter-over-quarter from $5.0 billion in Q4 2025.
AbbVie (ABBV) Inventory (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has 15 years of Inventory data on file, last reported at $5.0 billion in Q1 2026.
- Inventory for Q1 2026 came in at $5.0 billion, up 11.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.0 billion (up 11.56% YoY), and the FY2025 annual result was $5.0 billion, up 18.42% from the prior year.
- Inventory climbed to $5.0 billion in Q1 2026 per ABBV's latest filing, from $5.0 billion in the prior quarter.
- Over five years, Inventory peaked at $5.0 billion in Q1 2026 and troughed at $3.2 billion in Q3 2022.
- A 5-year average of $4.2 billion and a median of $4.2 billion in 2024 frame the typical range for Inventory.
- The sharpest annual moves came in 2022 and 2023: Inventory advanced 0.3% in 2022, then advanced 25.5% in 2023.
- A 5-year view of Inventory shows it stood at $3.6 billion in 2022, then increased by 14.53% to $4.1 billion in 2023, then grew by 2.0% to $4.2 billion in 2024, then gained by 18.42% to $5.0 billion in 2025, then gained by 1.98% to $5.0 billion in 2026.
- Business Quant data shows ABBV's Inventory at $5.0 billion in Q1 2026, $5.0 billion in Q4 2025, and $4.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 8.30 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 14.53 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 14.58 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 5.05 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 6.48 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 6.19 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 1.91 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 10.67 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 2.76 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.05 Bn |
| Dec 31, 2025 | 4.95 Bn |
| Sep 30, 2025 | 4.94 Bn |
| Jun 30, 2025 | 4.96 Bn |
| Mar 31, 2025 | 4.53 Bn |
| Dec 31, 2024 | 4.18 Bn |
| Sep 30, 2024 | 4.45 Bn |
| Jun 30, 2024 | 4.22 Bn |
| Mar 31, 2024 | 4.25 Bn |
| Dec 31, 2023 | 4.10 Bn |
| Sep 30, 2023 | 3.98 Bn |
| Jun 30, 2023 | 4.06 Bn |
| Mar 31, 2023 | 3.83 Bn |
| Dec 31, 2022 | 3.58 Bn |
| Sep 30, 2022 | 3.17 Bn |
| Jun 30, 2022 | 3.40 Bn |
| Mar 31, 2022 | 3.48 Bn |
| Dec 31, 2021 | 3.13 Bn |
| Sep 30, 2021 | 3.09 Bn |
| Jun 30, 2021 | 3.39 Bn |